Recognition from TIME and Statista highlights Cala’s leadership in medical devices with its Cala TAPS  wearable for essential tremor and Parkinson’s disease

SAN MATEO, Calif., Sept. 17, 2026 /PRNewswire/ — Cala^®, the bioelectronic medicine leader, today announced it has been named to TIME and Statista’s World’s Top HealthTech Companies 2026 list in the Medical Devices & Wearables Category. Cala TAPS^® therapy, delivered from a wrist-worn wearable, is the most researched wearable treatment for essential tremor. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared the Cala kIQ^® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Cala kIQ Plus is the latest advancement in TAPS technology, introducing new therapy modes and adaptive calibration designed to optimize tremor relief and personalize treatment.

“Essential tremor affects over 7 million Americans, making daily living activities like eating, drinking, buttoning a shirt or brushing teeth challenging,” said Cala CEO Deanna Harshbarger. “Recognition as a world’s top healthtech company affirms Cala’s mission to provide tremor relief with our wearable that is accessible, reimbursed, non-invasive, and provides clinically proven and effective neuromodulation that is personalized to the specific tremor of each patient.”

About the TIME World’s Top Healthtech Companies List

Now in its second year, the list recognizes 500 HealthTech companies from more than 30 countries across six market segments: AI & Data Analytics, Diagnostics, Health Information & Management, Medical Devices & Wearables, Prevention, and Telehealth & Treatment. Rankings are based on a detailed evaluation of financial performance, reputation analysis, and online engagement, drawing on verified indicators such as revenue, employee count, disclosed funding, media coverage, and website-traffic performance over the past 24 months.

About Cala^®

Cala Health^® is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies.

The Cala kIQ^® Plus System is the only FDA-cleared wearable device that delivers effective therapy for action hand tremor in people with essential tremor and Parkinson’s disease. The Cala kIQ device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson’s disease. The Cala kIQ Plus device delivers TAPS™ therapy, which provides transcutaneous afferent patterned stimulation.

The Cala^® system is available by the Veterans Affairs (VA) Health System at no cost to eligible VA beneficiaries and has Medicare coverage for those who meet Local Coverage Criteria.  Cala continues to advocate on behalf of patients with ET and PD to secure additional coverage and reimbursement in Medicare Advantage and commercial payor plans.  

Caution: Federal law restricts this device to sale by or on the order of a physician. Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at https://calahealth.com/.

View original content:https://www.prnewswire.com/news-releases/cala-health-named-a-2026-worlds-top-healthtech-company-302882007.html

SOURCE Cala Health